The Nicotine Measuring Stick: How Do We Know If a Policy Is Working?
Tobacco control policies are evaluated by one metric: smoking prevalence. But what if that's the wrong metric? What if population-level nicotine satisfaction—not nicotine abstinence—is the better measure of whether we're helping or harming?
Every tobacco control policy, from cigarette taxes to flavor bans to PMTA requirements, is justified by a single metric: will it reduce smoking prevalence? The metric makes intuitive sense. Smoking is the behavior that causes disease, and reducing smoking is the goal. But the metric has a blind spot: it doesn't distinguish between a smoker who quits all nicotine and a smoker who switches to a reduced-risk product. Under the smoking-prevalence metric, both count as 'success'—the smoker is no longer a smoker. But the metric also doesn't capture the public health impact of policies that make reduced-risk products less accessible—policies that may reduce smoking prevalence by driving vapers back to smoking. **The smoking-prevalence metric is not wrong. It's incomplete—and the policies that are optimized for this single metric may be producing outcomes that look like success (smoking prevalence is declining) while masking failure (smokers who would have switched to reduced-risk products are continuing to smoke).**
**The alternative metric is population-level nicotine satisfaction—or, more precisely, population-level harm from nicotine consumption.** This metric would capture not just how many people smoke, but how they consume nicotine: combustible vs. non-combustible, high-risk vs. low-risk, satisfying vs. unsatisfying. A policy that drives smokers to switch to vaping would score well on the harm metric (the smokers are now consuming nicotine in a dramatically lower-risk form) even if the smoking-prevalence metric shows no change (the smokers are still 'smoking' in some surveys, or have become 'vapers' rather than 'abstainers'). A policy that restricts vaping access would score poorly on the harm metric (if it drives vapers back to smoking) even if the smoking-prevalence metric shows improvement (if some vapers quit all nicotine while others return to cigarettes). **The harm metric captures what the smoking-prevalence metric misses: the substitution between products with dramatically different risk profiles.**
**The resistance to the harm metric is institutional, not scientific.** The tobacco control establishment has defined success as 'a world without tobacco' for so long that any metric that accepts continued nicotine use as a legitimate outcome feels like surrender. The establishment's funding, its career structures, its advocacy strategies are all built around the smoking-prevalence metric. Adopting the harm metric would require acknowledging that some of the policies that reduced smoking prevalence—the flavor bans, the product restrictions, the precautionary communication—may have increased population-level harm by restricting the availability of reduced-risk alternatives. **The harm metric is not just a different way of measuring. It's a different way of thinking about what success looks like—and the institutions that have defined success as nicotine abstinence are not ready to acknowledge that the smokers who switch to vaping have achieved something valuable.**
**The metric debate has real-world consequences.** The UK evaluates its tobacco control policies using both smoking prevalence and 'quit success rates'—metrics that capture the transition from smoking to reduced-risk products. The US evaluates its policies almost exclusively through smoking prevalence—a metric that is blind to the substitution between products. The result: the UK has embraced vaping as a harm reduction tool and has some of the fastest-declining smoking rates in the world. The US has restricted vaping and celebrated the decline in youth vaping as a policy success—without measuring whether the restrictions have driven some adult vapers back to smoking. **The metric you choose determines the policies you pursue—and the smoking-prevalence metric, for all its intuitive appeal, is steering policy toward outcomes that may be harmful to the population it's supposed to help.**
**💬 What metric do you think should be used to evaluate nicotine policy—smoking prevalence, population-level harm, or something else?** Does it matter if a smoker quits all nicotine or switches to a reduced-risk product, as long as their health improves? And how should we measure success?
